Shaker Abdulaziz Alomary

Dr. Shaker Abdulaziz Alomary

Director-General of the General Directorate for Health Programmes and Chronic Disease,Ministry of Health, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2022 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
YAYousef Al-Saleh
Yousef Al-Saleh
RSRiad A. Sulimani
Riad A. Sulimani
Shaker Abdulaziz AlomaryShaker Abdulaziz Alomary
Shaker Abdulaziz Alomary
YAYassmeen I. Alnajjar
Yassmeen I. Alnajjar
LVLiesbeth Vandenput
Liesbeth Vandenput
TGthe Saudi FRAX Study Group
the Saudi FRAX Study Group
Summary A prospective hospital-based survey in representative regions of Saudi Arabia determined the incidence of fractures at the hip. The hip fracture rates were used to create a FRAX® model to facilitate fracture risk assessment in Saudi Arabia. Objective This paper describes the incidence of hip fracture in the Kingdom of Saudi Arabia that was used to characterize the current and future burden of hip fracture, to develop a country-specific FRAX® tool for fracture prediction and to compare fracture probabilities with neighbouring countries. Methods During a 2-year (2017/2018) prospective survey in 15 hospitals with a defined catchment population, hip fractures in Saudi citizens were prospectively identified from hospital registers. The number of hip fractures and future burden was determined from national demography. Age- and sex-specific incidence of hip fracture and national mortality rates were incorporated into a FRAX model for Saudi Arabia. Fracture probabilities were compared with those from Kuwait and Abu Dhabi. Results The incidence of hip fracture applied nationally suggested that the estimated number of hip fractures nationwide in persons over the age of 50 years for 2015 was 2,949 and is predicted to increase nearly sevenfold to 20,328 in 2050. Hip fracture rates were comparable with estimates from Abu Dhabi and Kuwait. By contrast, probabilities of a major osteoporotic fracture or hip fracture from the age of 70 years were much lower than those seen in Abu Dhabi and Kuwait due to higher mortality estimates for Saudi Arabia. Conclusion A country-specific FRAX tool for fracture prediction has been developed for Saudi Arabia which is expected to help guide decisions about treatment.

Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
Shaker Abdulaziz AlomaryShaker Abdulaziz Alomary
Shaker Abdulaziz Alomary
SASaeed Alqahtani
Saeed Alqahtani
IAIzzeldin F Adam
Izzeldin F Adam
SASamar Amer
Samar Amer
Since the emergence of the COVID-19 pandemic, the mortality statistics are constantly changing globally. Mortality statistics analysis has vital implications to implement evidence-based policy recommendations. This study aims to study the demographic characteristics, patterns, determinants, and the main causes of death during the first half of 2020, in the Kingdom of Saudi Arabia (KSA). Methodology: A retrospective descriptive study targeted all death (29,291) registered in 286 private and governmental health settings, from all over KSA. The data was extracted from the ministry of health’s death records after the ethical approval. The International Classification of Diseases (ICD-10) and WHO grouping, were used to classify the underlying causes of deaths. The collected data were analyzed using the appropriate tables and graphs. Results: 7055 (24.9%) died at the middle age (40–59 year), and 19,212 (65.6%) were males, and 18,110 (61.8%) were Saudi. The leading causes of deaths were non-communicable diseases (NCDs) 15,340 (62.1%), mainly Cardiovascular diseases (CVDs) 10,103 (34.5%). There was a significant relationship between the main causes of deaths and sex (p < 0.05) and nationality (p = 0.01). Conclusion: NCDs mainly CVDs are the leading cause of death. The COVID-19 mortalities were mainly in males, and old age > 55 year. The lockdown was associated with a reduction in the NCDs and Road traffic accidents mortalities.

22 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FTFatina Al Tahan
Fatina Al Tahan
Shaker Abdulaziz AlomaryShaker Abdulaziz Alomary
Shaker Abdulaziz Alomary
HTHani Tamim
Hani Tamim
MAMohammad Alkaiyat
Mohammad Alkaiyat
HNHaifa Nassri
Haifa Nassri
AJAbdul Rahman Jazieh
Abdul Rahman Jazieh

14 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
KAKholud R. Alrubaie
Kholud R. Alrubaie
RARaghad A. Alzaylaee
Raghad A. Alzaylaee
LALatifah A. Alayyaf
Latifah A. Alayyaf
FAFarjah Hassan Alqahtani
Farjah Hassan Alqahtani
Shaker Abdulaziz AlomaryShaker Abdulaziz Alomary
Shaker Abdulaziz Alomary
Mariam Mohammed Ali AlEissaMariam Mohammed Ali AlEissa
Mariam Mohammed Ali AlEissa
Pharmacogenomics has the potential to improve the safety and efficacy of medicines in Saudi Arabia, and has a strong basis for implementation through population-specific genomic evidence, growing laboratory capacity and national digital health investment. We undertook a structured policy analysis and evidence synthesis of Saudi, regional, and international evidence; compared selected implementation capabilities across established models; and assessed national readiness descriptively across key health system domains. Using published evidence and structured expert judgement, we propose gene–drug priority tiers according to their clinical impact, population relevance and feasibility. Saudi Arabia’s strengths are in genomic evidence and digital health infrastructure, but large gaps exist in governance, laboratory standardization, electronic health record interoperability, clinical decision support, workforce readiness, reimbursement, and outcome evaluation. Five pathways are proposed for initial implementation: CYP2C19–clopidogrel, DPYD–fluoropyrimidines, TPMT/NUDT15–thiopurines, HLA-guided anticonvulsant prescribing and HLA-B*57:01–abacavir. We propose a framework that could be supported by the Population Health Observatory and a six-phase roadmap, moving from governance and technical design to multicenter pilots, national scale-up and continuous evaluation.